Viridian Therapeutics, Inc.\de
A biotechnology company developing new treatments for thyroid eye disease, a rare autoimmune condition that makes the tissues behind the eye swell and bulge. Its lead experimental medicine, veligrotug, is an antibody designed to block the protein driving that swelling. The company was formed under its current name in 2022, taking "Viridian" from the green pigment, a nod to fresh growth.
Bought 1.63M
Sold 2.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC +2 co-filersDirector, 10% owner · 2 transactions | — | 9.01M | — | 1.63M | — |
| Mahoney Stephen F.President and CEO, Director · 1 transaction | +55.8% | 33.3K | — | — | — |
| Beetham Thomas W.Chief Operating Officer · 1 transaction | +122.7% | 13.4K | — | — | — |
| Harmon SethChief Financial Officer · 1 transaction | — | 1.7K | — | — | — |
| Tousignant JenniferChief Legal Officer · 2 transactions | — | 610 | — | — | 2.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +1.63M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.